What is AlloSeq™ cfDNA?

AlloSeq cfDNA is a kit-based blood test that measures the amount of donor-derived cell-free DNA (dd-cfDNA) in a transplant recipient to help determine the health of the transplanted organ. It is currently only available outside of the United States.

The kit is designed to allow your laboratory to implement the AlloSeq cfDNA surveillance solution.

  • Minimally invasive, kit-based test, with sample to report within 24 hours
  • Sensitive, accurate and precise measure of organ health to help drive better patient outcomes
  • A kit based test to run in your own lab and does not require prior genotyping

How does AlloSeq cfDNA work?

The kit is designed to allow your laboratory to implement the AlloSeq cfDNA surveillance solution

Cell-free DNA is fragmented DNA originating from cells and continuously released into the bloodstream


AlloSeq cfDNA measures cfDNA, and uses single nucleotide polymorphisms (SNPs) to distinguish between donor and recipient.


AlloSeq can quantify increasing levels of dd-cfDNA, serving as a leading indicator of graft injury

Clinical Utility of dd-cfDNA for transplant surveillance has been validated in the US with AlloSure

AlloSure is a dd-cfDNA surveillance service that is clinically and analytically validated for identifying kidney injury

AlloSure was clinically validated in the prospective, multi-center DART study conducted across 14 transplant centers across the United States. DART and over twenty subsequent publications and abstracts have demonstrated that AlloSure surveillance provides actionable information for patient management:

High NPV gives peace of mind to physicians and patients.

  • High PPV for ABMR in DSA+ patients2
  • Differentiates borderline/TCMR1A patients3
  • 95% NPV at 0.21% threshold1